175 related articles for article (PubMed ID: 25445472)
1. Relationship of P-selectin glycoprotein ligand-1 to prognosis in patients with multiple myeloma.
Atalay F; Ateşoğlu EB; Yıldız S; Firatlı-Tuglular T; Karakuş S; Bayık M
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):164-70. PubMed ID: 25445472
[TBL] [Abstract][Full Text] [Related]
2. Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma.
Ailawadhi S; Abdelhalim AN; Derby L; Mashtare TL; Miller KC; Wilding GE; Alberico RA; Gottlieb R; Klippenstein DL; Lee K; Chanan-Khan AA
Cancer; 2010 Jan; 116(1):84-92. PubMed ID: 19862816
[TBL] [Abstract][Full Text] [Related]
3. A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma.
Mai EK; Hielscher T; Kloth JK; Merz M; Shah S; Raab MS; Hillengass M; Wagner B; Jauch A; Hose D; Weber MA; Delorme S; Goldschmidt H; Hillengass J
Haematologica; 2015 Jun; 100(6):818-25. PubMed ID: 25795721
[TBL] [Abstract][Full Text] [Related]
4. The association between COX-2 expression and survival in myeloma patients.
Vural F; Soyer N; Hekimgil M; Cagirgan S; Donmez A; Tombuloglu M
Eur Rev Med Pharmacol Sci; 2014; 18(15):2132-6. PubMed ID: 25070817
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters.
Bhatti SS; Kumar L; Dinda AK; Dawar R
Am J Hematol; 2006 Sep; 81(9):649-56. PubMed ID: 16845660
[TBL] [Abstract][Full Text] [Related]
6. Cyclin D1 amplification in multiple myeloma is associated with multidrug resistance expression.
Sewify EM; Afifi OA; Mosad E; Zaki AH; El Gammal SA
Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):215-22. PubMed ID: 24468132
[TBL] [Abstract][Full Text] [Related]
7. Magnetic resonance imaging pattern of bone marrow involvement as a new predictive parameter of disease progression in newly diagnosed patients with multiple myeloma eligible for autologous stem cell transplantation.
Song MK; Chung JS; Lee JJ; Min CK; Ahn JS; Lee SM; Shin DY; Bae SH; Hong J; Lee GW; Lee IS; Shin HJ
Br J Haematol; 2014 Jun; 165(6):777-85. PubMed ID: 24628463
[TBL] [Abstract][Full Text] [Related]
8. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
9. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment.
Azab AK; Quang P; Azab F; Pitsillides C; Thompson B; Chonghaile T; Patton JT; Maiso P; Monrose V; Sacco A; Ngo HT; Flores LM; Lin CP; Magnani JL; Kung AL; Letai A; Carrasco R; Roccaro AM; Ghobrial IM
Blood; 2012 Feb; 119(6):1468-78. PubMed ID: 22096244
[TBL] [Abstract][Full Text] [Related]
10. Stage I multiple myeloma: value of MR imaging of the bone marrow in the determination of prognosis.
Van de Berg BC; Lecouvet FE; Michaux L; Labaisse M; Malghem J; Jamart J; Maldague BE; Ferrant A; Michaux JL
Radiology; 1996 Oct; 201(1):243-6. PubMed ID: 8816551
[TBL] [Abstract][Full Text] [Related]
11. Expression and function of P-selectin glycoprotein ligand 1 (CD162) on human basophils.
Taylor ML; Brummet ME; Hudson SA; Miura K; Bochner BS
J Allergy Clin Immunol; 2000 Nov; 106(5):918-24. PubMed ID: 11080715
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma.
Atanackovic D; Luetkens T; Hildebrandt Y; Arfsten J; Bartels K; Horn C; Stahl T; Cao Y; Zander AR; Bokemeyer C; Kröger N
Clin Cancer Res; 2009 Feb; 15(4):1343-52. PubMed ID: 19190130
[TBL] [Abstract][Full Text] [Related]
13. CXCR4 is a good survival prognostic indicator in multiple myeloma patients.
Bao L; Lai Y; Liu Y; Qin Y; Zhao X; Lu X; Jiang Q; Lu J; Huang X
Leuk Res; 2013 Sep; 37(9):1083-8. PubMed ID: 23849988
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of cyclooxygenase-2 in multiple myeloma: association with reduced survival.
Cetin M; Buyukberber S; Demir M; Sari I; Sari I; Deniz K; Eser B; Altuntas F; Camci C; Oztürk A; Turgut B; Vural O; Unal A
Am J Hematol; 2005 Nov; 80(3):169-73. PubMed ID: 16247750
[TBL] [Abstract][Full Text] [Related]
15. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
16. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma.
Korthals M; Sehnke N; Kronenwett R; Schroeder T; Strapatsas T; Kobbe G; Haas R; Fenk R
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1109-15. PubMed ID: 23644045
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and risk stratification in multiple myeloma.
van de Donk NW; Sonneveld P
Hematol Oncol Clin North Am; 2014 Oct; 28(5):791-813. PubMed ID: 25212883
[TBL] [Abstract][Full Text] [Related]
18. MYC protein expression is detected in plasma cell myeloma but not in monoclonal gammopathy of undetermined significance (MGUS).
Xiao R; Cerny J; Devitt K; Dresser K; Nath R; Ramanathan M; Rodig SJ; Chen BJ; Woda BA; Yu H
Am J Surg Pathol; 2014 Jun; 38(6):776-83. PubMed ID: 24705315
[TBL] [Abstract][Full Text] [Related]
19. Stage III multiple myeloma: clinical and prognostic value of spinal bone marrow MR imaging.
Lecouvet FE; Vande Berg BC; Michaux L; Malghem J; Maldague BE; Jamart J; Ferrant A; Michaux JL
Radiology; 1998 Dec; 209(3):653-60. PubMed ID: 9844655
[TBL] [Abstract][Full Text] [Related]
20. The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.
Paul B; Zhao Y; Loitsch G; Feinberg D; Mathews P; Barak I; Dupuis M; Li Z; Rein L; Wang E; Kang Y
Cancer Med; 2020 Aug; 9(16):5869-5880. PubMed ID: 32628819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
